Elinzanetant Provides VMS-Independent Sleep Improvement in Postmenopausal Women: Daily Dose
Your daily dose of the clinical news you may have missed.
CTAD 2025: Lecanemab Boosts CSF Aβ Protofibrils, Confirming Target Engagement and Pharmacodynamic Effect
New data reveals lecanemab's significant impact on amyloid-beta protofibrils in Alzheimer disease, showcasing its potential to slow disease progression.
Lifestyle Intervention Shows Benefits Beyond Cognition in US POINTER Trial, Highlighting Modifiable Risk Factors for Dementia
Two-year structured lifestyle "recipe" slowed cognitive aging and enhanced both cardiovascular and sleep health in older adults at risk for cognitive decline.
First Blood Test for Alzheimer Disease Diagnosis Cleared by FDA for Primary Care Use: Daily Dose
Why Caregivers Don't Talk About Alzheimer Agitation, With Geriatric NP Carolyn Clevenger, GNP
Nearly one-third of caregivers hesitate to discuss agitation in a patient with AD. Emory's Clevenger, shares why and how clinicians can proactively address this barrier.
New Menopause Therapies Reflect a “Sea Change” in Women’s Health, Says Lisa Larkin, MD
Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.
Baxdrostat Granted FDA Priority Review for Hard-to-Control Hypertension, Could Be First-In-Class Therapy
The Priority Review decision is based on phase 3 results showing consistent SBP reductions across uncontrolled and treatment-resistant hypertension subgroups.
Obesity Linked to Faster Alzheimer Disease Progression in Longitudinal Blood Biomarker Analysis
Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.
WHO Issues First Guidelines on GLP-1 Receptor Agonists for Obesity Treatment
The landmark global policy recognizes obesity as chronic disease requiring lifelong care, warns of inequitable access and proposes 3-pillar strategy targeting prevention, screening, treatment.
Understanding Agitation in Alzheimer's: Why Memory Care Isn't Enough – with Carolyn Clevenger, GNP
Emory's Clevenger discusses the neurotransmitter dysregulation behind agitation in AD and why memory-focused care doesn't address behavioral symptoms.
Treating Body and Mind in Atopic Dermatitis: Priorities for Primary Care
Psychiatric comorbidities affect 25% of AD patients. Here, a check list on when to screen, when to refer, and how to prevent accumulated psychological burden in primary care.
Merck Secures Fast Track for Novel AD Antibody and Reports First-in-Human Data
New safety and biomarker results from MK-2214 and MK-1167 advance Merck’s dual approach to Alzheimer therapy.
Galcanezumab Efficacy and Safety Confirmed in Meta-Analysis of Real-World Studies
Two-thirds of participants experienced clinically meaningful response within 3 months; effects sustained through 12 months with mild adverse event profile.
Evolocumab Associated with Lower Long-term Cardiovascular Event Risk in Real-world Study of More Than 110 000 Patients
New data reveals evolocumab significantly reduces long-term major cardiovascular event risks in ASCVD patients, enhancing treatment strategies for better outcomes.
FDA's Vaccine Chief Prasad Links Pediatric Deaths to COVID-19 Shots, Proposes Stricter Regulatory Framework
Former CBER chief calls claims "misrepresentation." ID experts Offit and Osterholm criticize timing ahead of CDC advisory committee meeting next week.
Geriatric NP Carolyn Clevenger Discusses Agitation in Alzheimer Disease: Overlooked, Misunderstood, and Progressive
Clevenger reviews survey findings behind the recent report "The Agitation Blindspot in Alzheimer’s Care."
Atopic Dermatitis Management Beyond Skin Symptoms in Primary Care
A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.
Benzodiazepines, Antipsychotics Linked to Increased Death in Dementia Hospice: Daily Dose
Meta-Analysis Finds High Uptake but Moderate Adherence in Clinical Trials of Depression and Anxiety Apps
Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.
Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management
Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Meta-Analysis Finds High Uptake but Moderate Adherence in Clinical Trials of Depression and Anxiety Apps")
